17 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 9 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Active not recruiting 1 |
| Phase 1 | 8 | Completed 6, Recruiting 1, Terminated 1 |
Follow Recurrent Childhood Soft Tissue Sarcoma: new trials by email Literature Review of Recurrent Childhood Soft Tissue Sarcoma trials Research Report on Recurrent Childhood Soft Tissue Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Functional Precision Medicine - Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Florida International University | 65 | 2023-02-22 | 2026-08-26 |
| Ex Vivo Drug Sensitivity Testing and Mutation Profiling Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Completed | Florida International University | 25 | 2019-02-21 | 2023-05-10 | |
| Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-06-05 | 2026-10-16 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas laboratory biomarker analysis - Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma | Completed | Children's Oncology Group | 70 | 2016-05-01 | 2016-05-17 | |
| Trabectedin and Irinotecan for Refractory Pediatric Sarcomas Combined chemotherapy with trabectedin followed by irinotecan - Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma | Unknown | Technical University of Munich | 30 | 2014-02-01 | 2015-07-27 | |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Bevacizumab, Cetuximab, Laboratory Biomarker Analysis - Advanced Malignant Neoplasm, Castleman Disease | Phase 1 | Terminated | M.D. Anderson Cancer Center | 154 | 2012-10-16 | 2026-05-15 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 118 | 2011-02-01 | 2020-05-13 |
| Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment pazopanib hydrochloride, pharmacological study - Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 55 | 2009-06-01 | 2013-09-30 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2009-01-01 | 2015-03-30 |
| Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2008-06-01 | 2016-05-17 |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 50 | 2008-01-01 | 2018-09-14 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors ixabepilone - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 120 | 2006-04-01 | 2014-11-14 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas irinotecan hydrochloride, oxaliplatin - Childhood Burkitt Lymphoma, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-06-05 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 180 | 2004-10-01 | 2013-06-05 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors tanespimycin, pharmacological study, laboratory biomarker analysis - Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 70 | 2004-09-01 | 2013-06-04 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors erlotinib hydrochloride, temozolomide, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 95 | 2004-02-01 | 2013-06-05 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood imatinib mesylate, laboratory biomarker analysis, pharmacological study - Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 100 | 2002-05-01 | 2015-04-15 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas alvocidib, pharmacological study - Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2001-04-01 | 2013-07-02 |
Showing 20 of 21. Sign in to see all of them.
Neuroblastoma (11) · Neuroectodermal Tumors, Primitive, Peripheral (11) · Osteosarcoma (11) · Sarcoma (9) · Familial ependymoma (8) · Rhabdomyosarcoma (7) · Wilms Tumor (6) · Desmoplastic Small Round Cell Tumor (5) · Hepatoblastoma (5) · Medulloblastoma (5) · Astrocytoma (4) · Dendritic Cell Sarcoma, Interdigitating (4) · Optic Nerve Glioma (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Fibrosarcoma (3)
Neoplasms by Histologic Type (21) · Neoplasms (19) · Neoplasms, Connective and Soft Tissue (17) · Neoplasms, Germ Cell and Embryonal (17) · Neoplasms, Connective Tissue (16) · Neoplasms, Nerve Tissue (16) · Neoplasms, Glandular and Epithelial (15) · Neoplasms, Neuroepithelial (14) · Neuroectodermal Tumors (14) · Neoplasms, Bone Tissue (13) · Neuroectodermal Tumors, Primitive (13) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9)
cixutumumab (3) · Oxaliplatin (2) · Sirolimus (2) · temsirolimus (2) · Bevacizumab (1) · Biopsy (1) · Cetuximab (1) · Disulfides (1) · Doxorubicin (1) · Erlotinib Hydrochloride (1) · Imatinib Mesylate (1) · Immunoglobulin G (1) · Irinotecan (1) · MLN 8237 (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (13) · Children's Oncology Group (4) · Florida International University (2) · M.D. Anderson Cancer Center (1) · Technical University of Munich (1)
United States (20) · Canada (5) · Puerto Rico (3) · Australia (2) · Netherlands (1) · New Zealand (1) · Switzerland (1)
Julia Glade-Bender (2) · Alice Lee (1) · Brenda Weigel, MD (1) · Brigitte Widemann (1) · Daria Salyakina, PhD (1) · Diana Azzam (1) · Diana Azzam, PhD (1) · James Whitlock (1) · Lars Wagner (1) · Lisa McGregor (1) · Maggie Fader (1) · Mason Bond (1) · Orren Beaty (1) · Rashmi Chugh (1) · Regina Jakacki (1)
PMID 31401903, PMID 22088484, PMID 23857966, PMID 25858498, PMID 30777875, PMID 34435684, PMID 34738048, PMID 37311055, PMID 38605166, PMID 38815151, PMID 41389341
U10CA098543 (7), U01CA097452 (4), U10CA180886 (2), N01CM00071 (1), P30CA014599 (1), U01CA069856 (1), U10CA024507 (1), U54MD012393 (1), UG1CA189958 (1), UM1CA081457 (1)